相关实验视频

Updated: Jul 17, 2025

Modified Experimental Conditions for Noise-Induced Hearing Loss in Mice and Assessment of Hearing Function and Outer Hair Cell Damage

Modified Experimental Conditions for Noise-Induced Hearing Loss in Mice and Assessment of Hearing Function and Outer Hair Cell Damage

Published on: February 10, 2023

甲福明可以保护雄性小鼠免受噪音引起的听力损失

Catherine L Kennedy¹, Benjamin Shuster², Reza Amanipour²

¹Department of Otorhinolaryngology-Head and Neck Surgery, University of Maryland School of Medicine, Baltimore.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology

|August 29, 2023

概括

梅特福林保护雄性小鼠免受噪音引起的听力损失,但不是雌性小鼠. 这凸显了在评估药物对听力保护的有效性时需要考虑性别差异的必要性.

科学领域:

耳鼻喉科耳鼻喉科耳鼻喉科
药理学药理学是指药理学的学科.
神经科学是一个神经科学.

背景情况:

噪音引起的听力损失 (NIHL) 是一个严重的健康问题.
美国食品和药物管理局 (FDA) 批准的一种药物梅特福明 (Metformin) 之前被确定为对内耳损伤的潜在治疗剂.
这项研究旨在功能性地评估甲福林对NIHL的自身保护能力.

研究的目的:

为了确定甲福明是否可以预防因噪音暴露引起的听力损失.
调查甲胺对NIHL的性别依赖性影响.
评估甲福明对耳组织和听觉功能的影响.

主要方法:

雄性和雌性小鼠,包括卵巢切除的雌性,都暴露在噪音 (102.5或105 dB SPL,8-16 kHz,2小时).
在暴露于噪音后,在饮用水中注入甲胺 (200 mg/kg/d) 或盐水.
分析了听觉脑干响应 (ABR) 值和耳外毛细胞损失.

主要成果:

在雄性小鼠中,甲福林显著降低了16和24kHz的ABR值变化.
在32-45.5 kHz范围内的雄性小鼠中,甲胺治疗也减少了外皮毛细胞的损失.
在完整的或经过卵巢切除的雌性小鼠中,没有观察到甲福明的显著保护作用.

结论:

甲胺在防止噪音引起的听力损失方面表现出取决于性别的有效性.
这些发现强调了在药物疗效研究中将性别视为生物变量的重要性.
需要进一步的研究来探索甲胺在NIHL的治疗潜力.

更多相关视频

Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice

Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice

Published on: January 9, 2019

Data Acquisition and Analysis In Brainstem Evoked Response Audiometry In Mice

Data Acquisition and Analysis In Brainstem Evoked Response Audiometry In Mice

Published on: May 10, 2019

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...